NADAC acquisition cost data for MERCAPTOPURINE 50 MG TABLET. This is a generic medication, typically more affordable than brand-name equivalents.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 00054458111 | $0.8521 | 2022-12-21 | Rx |
| 00054458127 | $0.8521 | 2022-12-21 | Rx |
| 00378354725 | $0.8521 | 2022-12-21 | Rx |
| 00378354752 | $0.8521 | 2022-12-21 | Rx |
| 69076091302 | $0.8521 | 2022-12-21 | Rx |
| 69076091325 | $0.8521 | 2022-12-21 | Rx |
| 00054458111 | $0.8521 | 2022-12-21 | Rx |
| 00054458127 | $0.8521 | 2022-12-21 | Rx |
| 00378354725 | $0.8521 | 2022-12-21 | Rx |
| 00378354752 | $0.8521 | 2022-12-21 | Rx |
Generic: Mercaptopurine | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $9.4M | 67,363 | 13,788 | $2.00 |
| 2020 | $8.9M | 61,524 | 12,828 | $1.98 |
| 2021 | $7.4M | 55,454 | 12,271 | $1.75 |
| 2022 | $6.8M | 49,519 | 11,314 | $1.77 |
| 2023 | $5.7M | 45,191 | 10,603 | $1.62 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| California | $667.2K | 5,417 | 1,413 |
| New York | $587.1K | 5,372 | 1,204 |
| Florida | $428.0K | 3,057 | 785 |
| Pennsylvania | $349.5K | 2,880 | 611 |
| Ohio | $264.7K | 1,664 | 391 |
| Texas | $250.5K | 1,809 | 442 |
| North Carolina | $244.0K | 1,955 | 447 |
| New Jersey | $230.4K | 1,653 | 421 |
| Massachusetts | $221.9K | 1,705 | 443 |
| Connecticut | $180.9K | 1,248 | 315 |
| Illinois | $160.1K | 1,390 | 345 |
| Wisconsin | $151.9K | 1,233 | 283 |
| Michigan | $147.7K | 1,240 | 295 |
| Georgia | $142.4K | 1,162 | 298 |
| Missouri | $118.0K | 895 | 233 |
| Minnesota | $117.1K | 863 | 211 |
| Arizona | $110.7K | 703 | 205 |
| Tennessee | $110.5K | 825 | 229 |
| Virginia | $86.0K | 624 | 172 |
| Indiana | $83.5K | 524 | 136 |
| South Carolina | $77.1K | 639 | 156 |
| Maryland | $72.4K | 592 | 152 |
| Washington | $69.0K | 616 | 147 |
| Oregon | $63.3K | 520 | 119 |
| Kentucky | $58.4K | 461 | 104 |
| Colorado | $55.7K | 349 | 93 |
| Oklahoma | $55.1K | 423 | 100 |
| Nebraska | $53.5K | 588 | 113 |
| Arkansas | $49.2K | 491 | 97 |
| Louisiana | $47.5K | 434 | 84 |
| Alabama | $43.8K | 371 | 78 |
| New Mexico | $40.9K | 284 | 71 |
| Nevada | $40.2K | 284 | 68 |
| Kansas | $40.1K | 357 | 87 |
| Maine | $39.2K | 271 | 64 |
| New Hampshire | $35.1K | 281 | 68 |
| Iowa | $30.2K | 277 | 67 |
| Idaho | $28.5K | 210 | 46 |
| Utah | $24.4K | 189 | 54 |
| Rhode Island | $24.1K | 183 | 40 |
| Vermont | $17.6K | 116 | 25 |
| West Virginia | $16.1K | 190 | 42 |
| Mississippi | $16.0K | 151 | 33 |
| Puerto Rico | $14.9K | 112 | 22 |
| Montana | $13.8K | 106 | 28 |
| Hawaii | $11.4K | 89 | 23 |
| South Dakota | $10.9K | 117 | 24 |
| Alaska | $10.2K | 65 | 19 |
| Delaware | $8.2K | 70 | 22 |
| North Dakota | $6.5K | 66 | 17 |
| District of Columbia | $5.8K | 25 | 11 |
| Wyoming | $3.9K | 36 | 11 |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.